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Abstract
Background: HMG-CoA reductase inhibitors (statins) are commonly used in medicine to control
blood lipid disorder. Large clinical trials have demonstrated that statins greatly reduces
cardiovascular-related morbidity and mortality in patients with and without coronary artery
disease. Also, the use of HMG-CoA reductase inhibitors has been reported to have
immunosuppressive effects.
Case presentation: We describe an unusual case of regression of vitiligo in a patient treated with
high dose simvastatin. The relation between simvastatin and regression of vitiligo in this case report
may be related to the autoimmune pathophysiology of the disease.
Conclusion:  This unexpected beneficial impact provides another scientific credence to the
hypothesis that immune mechanisms play a role in the development of vitiligo and that the use of
statins as immuno-modulator could be of use not only for treatment relative to organ transplant
but in other pathologies such as vitiligo.
Case report
A 55 year-old man was recruited in a clinical trial where
medications have to be weaned. He had suffered from pre-
vious myocardial infarcts in 1988, 1992 and 1999. The
subject is an ex smoker and is intolerant to aspirin and
non-steroidal anti-inflammatory medication since the age
of 28 years. He has also been diagnosed with vitiligo since
he was 31 year old. Skin depigmentation has been mostly
present on the face, chest and hands areas. Numerous
treatment have been tried to alleviate the vitiligo without
success. Strangely, the patient mentioned that signs of
vitiligo was somewhat alleviated after he was given an
HMG-CoA reductase (simvastatin) to control high blood
cholesterol levels.
The subject had been treated with metoprolol (Lopressor®;
Novartis Pharmaceutical, New York, USA) 50 mg per os
BID and clopidogrel (Plavix®; Bristol-Myers Squibb, New-
York, USA) 75 mg per os OD since October 1999 as well
as simvastatin (Zocor®; Merck Frosst, New Jersey, USA) 80
mg at bedtime since September 2000.
Except for mild skin signs of vitiligo, mainly in the face
and hands, physical examination upon entry in the study
was normal with blood pressure at 120/80 mmHg and
elevated low-density lipoprotein (LDL) cholesterol of
4.37 mmol/L, high-density lipoprotein (HDL) of 1.2
mmol/L and triglycerides (TG) concentrations at 1.9
mmol/L.
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Clinical trial (start date: March 28th 2001)
According to the study protocol requirement, simvastatin
was stopped on March 28th, 2001 until May 18th, 2001
when atorvastatin (Lipitor®; Pfizer; New York, USA) 10 mg
per os OD was introduced. Five days later, on May 23rd,
2001, following the subject's request and the study physi-
cian recommendation, the subject was pulled out of the
study due to the study medication's side effects (head-
aches). At the physical exam of May 23rd, 2001, it was
noticed by the physician and reported by the subject that
skin depigmentation secondary to vitiligo had increased
significantly since the entry in the study two months ear-
lier especially in the face area. Following the study dis-
charge, atorvastatin was stopped and simvastatin re-
started at a dosage of 80 mg at bedtime. Later, consent
form was obtained from the subject and pictures taken on
July 18th, 2001 (Figure 1). At this point in time, the subject
had recently started his medication and clear signs of skin
depigmentation, comparable to those found at the physi-
cal exam 55 days ago, were still present. The subject
returned for pictures on November 22nd, 2001 and August
21st, 2002 to compare the progression of his vitiligo in the
summer and in the winter season (Figure 1). As compared
in Figure 2, a clear regression of the skin's depigmentation
of the face was noticeable between the sets of pictures
when the subject was on and off simvastatin. Of notes, all
other drugs were kept unchanged.
Timeline progression of the vitiligo Figure 1
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Discussion
Vitiligo is an acquired skin depigmenting disorder charac-
terized by the loss of melanocytes, exocrine cells, from
basal layer of the epidermal and the matrix portion of the
hair bulb. It results in well-defined white patches, often
symmetrically distributed. Vitiligo occurs worldwide in
Subject's picture showing a positive and unattended side effect of simvastatin on skin depigmenting disorder called vitiligo Figure 2
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about 1% of the population, mostly man between the age
of 10–30 years regardless of race, but more troublesome
in dark skin individuals. So far, the cause of vitiligo has
remained unknown but might involve genetic factors,
autoimmunity (lopecia areata, thyroid disorders, Addi-
son's adrenal disease, atrophic gastritis, pernicious anae-
mia, and diabetes), toxic metabolites and/or a higher
vulnerability of melanocytes [1].
HMG-CoA reductase inhibitors (statins) are commonly
used in medicine to control blood lipid disorder. Large
clinical trials have demonstrated that statins greatly
reduces cardiovascular-related morbidity and mortality in
patients with and without coronary artery disease [2-4].
After its ingestion, the inactive lactone is hydrolysed in β-
hydroxyl acid and inhibits the hydroxy-3 methyl-3 glu-
taryl coenzyme A (HMG-CoA) reductase [5]. The role of
the regulatory enzyme HMG-CoA essentially limits the
mevalonate pathway through which cells synthesize cho-
lesterol. Although the pharmacokinetics and the meta-
bolic pathway of simvastatin are complex, it basically
reduces the synthesis of LDL cholesterol by the liver and
other cells and increases its catabolism [5].
Vitiligo, an autoimmune disease
The relation between simvastatin and regression of vitil-
igo in this case report may be related to the autoimmune
pathophysiology of the disease. This hypothesis is sup-
ported by the frequent association of vitiligo with autoim-
mune diseases [6] and studies demonstrated that most
vitiligo patients have antibodies against melanocytes [7].
Although the application of the following animal model
to the human disorder remains to be better establish, the
Smyth line chicken model who depicts spontaneous post-
natal expression of vitiligo showed an increase in T cells in
the feather pulp and circulating inflammatory leukocytes
[8]. In human, circulating antibodies and T lymphocytes
which react against melanocyte antigens are present in the
sera of patient with vitiligo [9] and higher proportion of
activated peripheral T cells, as determined by the expres-
sion of HLA-DR, has also been found in patients with
vitiligo compared to healthy individual [10]. In a study of
49 biopsies from the margin of depigmented cutaneous
lesions, the expression of Major Histocompatibility Com-
plex class II (MHC-II) antigens demonstrates activation of
the infiltrating T cells [11]. Lesional T cells rather than cir-
culatory anti-melanocytic antibody may also be responsi-
ble for the autoimmune patchy destruction on cutaneous
melanocytes in vitiligo [11]. When compared to healthy
individuals, a significant proportion of patients with vitil-
igo had circulating antibodies and T lymphocytes, which
react against melanocytes antigen present in the sera [1].
Indeed, it has been reported that normal melanocytes are
capable of presenting antigenic peptide fragment to well-
defined proliferative cytotoxic T cells in a MHC class II-
restricted manner [12]. Therefore, since these molecules
have important roles in normal antigen presentation and
the activation of helper T lymphocytes, their expression by
the melanocytes may contribute to the abnormal cellular
immune response seen in vitiligo. Kawakami et al. [13]
further confirmed that T cells specific response for
melanoma cells and melanocytes appear to be involved in
the rejection of melanoma tumour as well as in the devel-
opment of autoimmune reaction of patient with vitiligo.
Since a number of reasonably effective therapies for vitil-
igo (psoralen with ultraviolet A radiation, topical corticos-
teroids and topical cytotoxic drugs) are
immunosuppressive in their mode of action, animal mod-
els of the disease and the association of vitiligo with MHC
antigens, we reasonably speculate that immune mecha-
nisms may play a major role in the development of
vitiligo.
Use of simvastatin as immunomodulator
Interestingly, the use of lipid lowering agent, specifically
HMG-CoA reductase inhibitors, has been reported to have
immunosuppressive effects in a study of heart transplant
recipients [14]. The drug-induced reduction of LDL cho-
lesterol may lead to more free cyclosporin in the blood
where its immunosuppressive effect is due to blockade of
interleukin-2 synthesis in activated T lymphocytes [15].
Kwak et al. [16] showed that statins act as direct inhibitors
of the induction of MHC-II expression by interferon-
gamma (IFN-γ) and thus as repressor of MHC-II mediated
T-lymphocytes activation in human endothelial cells.
Using RNAse protection assay and flow cytometry, it was
observed that simvastatin, in a dose dependent fashion,
reduced IFN-γ induced MHC-II expression (mRNA and
protein) through actions on the CIITA promoter I [17]. It
is important to note that the subject of this case report was
on a high dose of simvastatin (80 mg OD). Regulation of
the expression of MHC-II genes is highly complex, and
this tight control directly affects the T-lymphocyte activa-
tion and thus the modulation of the immune response.
Consequently, by repressing the induction of MHC-II,
and subsequent T lymphocytes activation, the action of
HMG-CoA reductase inhibitor, mostly used as lowering
blood cholesterol agent, may provide new type of
immuno modulation as suggested by our case report and
literature on organ transplant recipients.
Conclusion
We describe an unusual case of regression of vitiligo in a
patient treated with high dose simvastatin. This unex-
pected beneficial impact provides another scientific cre-
dence to the hypothesis that immune mechanisms play a
role in the development of vitiligo and that the use of stat-
ins as immuno-modulator could be of use not only for
treatment relative to organ transplant but in other pathol-
ogies such as vitiligo. However, even though reducedPublish with BioMed Central    and   every 
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chronic rejection and decreased graft arteriosclerosis was
seen in rats recipients of heterotopic heart transplant
[18,19] and a reduction of acute rejection reactions was
documented in pravastatin-treated human subjects com-
pared with controls receiving only prednisone, azathio-
prine and cyclosporine [20], caution should be use when
associating statins in purely immune-related pathologies.
Other clinical trials have failed to demonstrate clinical
benefits of statins as immuno-modulators in transplant
patients [1]. Therefore, a prospective study should be ini-
tiated to try to answer the hypothesis associating the use
of statins as an immuno-modulator for the treatment of
vitiligo.
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